drugset / Trial / NCT04944290

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290

Phase 3 Completed 447 enrolled Padagis LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.

Timeline

Start
2021-05-28
Primary completion
2022-03-11
Completion
2022-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Other
Subject Brinzolamide Small molecule 1 % Other